Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.


The additional data presented today for the first time focused on other patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include serum albumin levels, white blood cell (WBC) count and temperature, and non-BI (NAP1/027) strains. The data showed that fidaxomicin overall demonstrated a lower recurrence rate compared to oral vancomycin (Vancocin(R)) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains. Vancocin is currently the only FDA approved therapy for CDI.

Recurrence Rates by Subgroup (per protocol)

    Risk Factors                         Fidaxomicin     Vancocin(R) capsules
                                         (200mg bid)         (125mg qid)
    White Blood Cell Count /Temp
    WBC < 15,000 uL and Temp
     < 38 degrees C                     10.7% (17/159)      22.4% (35/156)
    WBC 15-25,000 uL or Temp 38
     degrees - 39 degrees C             12.0% (3/25)        20.0% (6/30)
    WBC > 25,000 uL or Temp
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
(Date:10/7/2015)... ... ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal Stem Cells and ... pm to 4:30 pm. , Dr. Riordan is one of the early pioneers and ... Co-Founder and Chief Science Officer of the Riordan-McKenna Institute of Regenerative Orthopedics ...
(Date:10/7/2015)... --  PDI , a leader in infection prevention products ... challenges across various healthcare settings, as well as guidelines ... tool is part of a larger effort to raise ... and lower healthcare-associated infections. ... how to use the right product, in the right ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , ... Coatings to provide a comprehensive overview of the innovations in smart coatings using ... . This webinar will be given by Professor Roberto Advincula, professor with ...
(Date:10/6/2015)... ... October 06, 2015 , ... ... new microscope technology that could help surgeons work with a greater degree of ... as blood flow and cancerous tissue over real images of blood vessels and ...
Breaking Biology Technology:
... IRVINE, Calif., Oct. 28 ChromaDex Corporation (OTC Bulletin ... development of phytochemical and botanical reference standards and the ... Company appointed William F. Spengler to President of the ... strong and diversified background to the position, having held ...
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: ... acquire the assets of the Neurovascular division of Boston ... which includes $100 million of milestone payments. The purchase ... the future tax benefit for Stryker based on the ...
... Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
Cached Biology Technology:
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics ... human interface solutions, announced today that it will ... fiscal 2016 on Thursday, October 22, 2015, after ... a corresponding conference call for analysts and investors ... which management may discuss forward-looking information.    ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/8/2015)... , October 8, 2015 ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet announces that revenues for ... approximately $410,000 compared with $113,00 for the three ... 9 months ended September 30, 2015 were approximately ...
Breaking Biology News(10 mins):
... WI, AUGUST 22, 2009 Bacteria commonly used to ... so reliable after all. Pathogenic E. coli were pervasive ... bacteria. This is one of the unexpected ... and resource managers rely on indicator bacteria to determine ...
... The University of Chicago will host a conference ... 150th anniversary of The Origin of Species and ... Darwin conference at Chicago, from Thursday, Oct. 29 ... University,s Fishbein Center for the History of Science, ...
... From book titles to real estate developments, it,s easier to ... define it. That,s why a Kansas State University geographer ... those who might be trying to work toward it. Her ... who have to make decisions about what to sustain with ...
Cached Biology News:
Synaptotagmin, phosphoSer309...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: